Tylenol Lawsuit: Tylenol Autism Lawsuit (June 2026)

As of May 2026, the Tylenol autism lawsuits remain in a critical and shifting phase, with federal Tylenol lawsuits largely dismissed while state court litigation continues moving forward. Estimated compensation values continue to vary widely, with projected settlements ranging from several hundred thousand dollars to potential multi-million-dollar verdicts in successful trial outcomes.

The scientific debate surrounding acetaminophen use during pregnancy also remains heavily contested. Some studies and medical organizations maintain there is no proven causal connection between Tylenol and autism or ADHD, while other research, including a Johns Hopkins study, found higher cord blood acetaminophen levels were associated with increased autism diagnoses. Major organizations like ACOG continue emphasizing that untreated fevers during pregnancy carry serious risks to both the mother and fetus.

As of January 2026, the Tylenol litigation remains active, heavily focused on expert admissibility and scientific causation issues, and upcoming developments are expected to shape the future of the cases. Courts continue examining whether plaintiffs’ experts can reliably testify about the alleged connection between prenatal acetaminophen exposure and neurodevelopmental disorders.

The outcome of these expert admissibility battles will likely determine whether additional lawsuits can move forward in either federal or state courts.

By late 2025, attorneys across the country continued filing Tylenol autism lawsuits despite the dismissal of the federal multidistrict litigation. 

Filing Tylenol lawsuits in state court accelerated as federal dismissals pushed many plaintiffs' attorneys into venues with different legal standards for expert evidence admissibility while they waited for developments in the federal appeals process.

Although no new MDL had been established, litigation activity continued expanding nationwide.

Recent weeks have brought increased state court acetaminophen lawsuits in Illinois, Florida, and Pennsylvania. Some of the newly filed cases include negligent misrepresentation claims against both manufacturers and retailers.

Plaintiffs remain hopeful that the Second Circuit will eventually reverse Judge Denise Cote’s earlier decision excluding expert testimony from the federal MDL. Many attorneys believe 2026 could become a pivotal year for Tylenol autism litigation.

Judge LeAnn Rafferty denied a motion by Kenvue and Johnson & Johnson seeking dismissal of legal action brought by Texas Attorney General Ken Paxton under state consumer-protection law.

The lawsuit alleges the companies used allegedly deceptive marketing to present Tylenol as safe during pregnancy despite being aware of numerous epidemiological studies suggesting a potential link between acetaminophen and autism.

The litigation also highlights how state laws may shape the future of Tylenol cases differently. Texas law contains safe harbor protections tied to FDA-approved warnings, while California law may allow broader liability theories.

The core theory is corporate accountability and product transparency, not that Tylenol is inherently defective. The lawsuit further alleges Johnson & Johnson transferred Tylenol liabilities to Kenvue to reduce future exposure tied to the autism litigation.

Learn More: New Lawsuit Against Johnson & Johnson and Janssen Pharmaceuticals, Risperdal Breast Cancer Lawsuits

A January 2026 review published in The Lancet found no causal link between acetaminophen use during pregnancy and autism after controlling for confounding factors, and it also concluded there was no increased risk of ADHD or other neurodevelopmental disorders. 

Similar no-connection findings have also been reported by researchers at Mount Sinai. However, critics quickly challenged both the study’s methodology and conclusions.

Some experts argued the sibling-control methodology may have diluted meaningful real-world effects, while others claimed the study ignored broader data supporting potential risks. Critics also emphasized that the study could not fully separate the effects of acetaminophen from the underlying illnesses or fevers that caused pregnant individuals to take the medication.

One of the most important developments to watch in 2026 is the pending Second Circuit Court of Appeals decision regarding the dismissal of the federal Tylenol autism MDL.

If the appellate court reverses Judge Cote’s ruling, thousands of claims could move forward again in federal court. If the dismissal is upheld, future litigation will likely continue primarily through individual state court lawsuits instead of a consolidated federal MDL.

The Second Circuit Court of Appeals was scheduled to hear oral arguments regarding whether the Tylenol autism MDL should be revived after its dismissal, in an appeal of an acetaminophen lawsuit. Multiple appellate judges appeared skeptical of the trial court’s decision to exclude plaintiffs’ expert testimony entirely.

Judges discussed whether at least some of the plaintiffs’ expert opinions should have been evaluated by a jury rather than excluded outright. During the same period, the FDA also announced efforts to add pregnancy warnings to acetaminophen products regarding potential neurodevelopmental risks.

The potential connection between Tylenol and autism returned to the national spotlight following new actions by the FDA and the Department of Health and Human Services, as growing FDA and state-level scrutiny increased pressure on acetaminophen manufacturers to evaluate and disclose emerging scientific data more proactively.

Consumers may soon see new cautionary labels on Tylenol and generic acetaminophen packages regarding prenatal use.

In September 2025, President Donald Trump announced that the FDA would notify doctors of a potential connection between prenatal Tylenol use and the development of autism and ADHD, while federal regulators also said label updates were being planned for acetaminophen products.

Plaintiffs in the litigation also pointed to these federal developments during the pending appeal, arguing that government agencies themselves were now relying on some of the same scientific research previously excluded by Judge Cote.

Reports emerged that the Department of Health and Human Services was preparing to release a report discussing a possible connection between prenatal Tylenol use and autism. The development came as the Second Circuit prepared to hear arguments regarding whether the federal lawsuits should be revived.

The litigation had remained largely stalled since Judge Cote excluded plaintiffs’ experts and granted summary judgment to the defendants in 2024.

As of late August 2025, the Second Circuit had still not issued a ruling on the pending appeal involving the Tylenol autism MDL. The litigation remained in limbo while families waited to learn whether the federal cases would be reinstated.

Meanwhile, plaintiffs continued pursuing claims in state courts, where judges may apply different standards to expert evidence and causation testimony.

With the federal MDL stalled pending appeal, many plaintiffs began pursuing Tylenol autism claims in state courts across the country, including California, Illinois, Delaware, New Jersey, and Pennsylvania.

Attorneys continued emphasizing that the Second Circuit’s decision would likely determine whether federal litigation resumes or whether state court actions become the primary avenue for future claims.

As of June 25, 2025, the Tylenol Autism Multidistrict Litigation remained in a holding pattern, with the MDL docket effectively paused while plaintiffs’ appeal continued before the Second Circuit Court of Appeals.

The appeal challenges Judge Denise Cote’s decision excluding all five of the plaintiffs’ general causation experts, which effectively ended the federal MDL.

The litigation’s future continues to depend heavily on whether the appellate court reverses or affirms that ruling.

As of May 30, 2025, the Second Circuit still had not issued a ruling on the plaintiffs’ appeal challenging the dismissal of the Tylenol autism MDL. The appeal focuses on Judge Cote’s decision to exclude plaintiffs’ expert testimony under federal evidentiary standards.

Families and attorneys continue waiting for the appellate court’s decision, which could either revive the federal litigation or leave plaintiffs limited primarily to state court claims.

The federal Tylenol autism MDL remained in limbo throughout early 2025 as plaintiffs awaited a ruling from the Second Circuit Court of Appeals. The appeal stems from Judge Denise Cote’s 2023 decision excluding plaintiffs’ expert testimony and dismissing the litigation.

Plaintiffs continue arguing that prenatal exposure to acetaminophen increases the risk of autism spectrum disorder and ADHD. In the meantime, attorneys have increasingly explored state court litigation while waiting for a federal appellate ruling.

The Second Circuit Court of Appeals had still not issued a decision regarding the dismissal of the Tylenol autism MDL as of April 2025. Oral arguments were previously held after Judge Cote excluded plaintiffs’ expert testimony and dismissed the litigation in late 2023.

The appeal challenges whether the court properly excluded expert opinions linking prenatal acetaminophen exposure to autism and ADHD diagnoses.

While families continued waiting for a ruling on the federal Tylenol autism MDL appeal, attorneys also remained involved in litigation involving toxic baby food products allegedly linked to autism and ADHD.

The pending appellate decision remained the most significant factor determining whether federal Tylenol autism claims would continue moving forward.

As of February 2025, plaintiffs still had not received a ruling from the appellate court regarding reinstatement of the federal MDL. In the meantime, attorneys continued exploring state court litigation as a possible path forward for families pursuing Tylenol autism claims.

State courts may apply different standards regarding expert testimony and admissibility issues compared to federal courts.

Families continued filing Tylenol autism lawsuits in state courts throughout early 2025 while awaiting the appellate court’s decision regarding Judge Cote’s dismissal of the federal MDL.

At the same time, additional litigation involving toxic baby food manufacturers and alleged heavy metal exposure continued expanding nationwide.

Although the appellate court had not yet issued a ruling regarding the dismissed federal MDL, Tylenol autism lawsuits continued being filed in state courts across the country.

Families seeking compensation continued exploring whether they qualified for either Tylenol autism litigation or toxic baby food autism claims involving alleged heavy metal exposure.

Plaintiffs formally appealed Judge Denise Cote’s decision excluding expert testimony regarding the alleged connection between prenatal Tylenol use and autism or ADHD diagnoses.

The appeal argues Judge Cote improperly applied the Daubert standard. According to the plaintiffs, the court acted as the ultimate scientific decision-maker instead of simply determining whether their experts’ methodologies met admissibility requirements.

The appeal also challenges the court’s handling of proposed warning language about prenatal acetaminophen risks. Plaintiffs argue that those warnings should have been allowed or considered for product labels.

Plaintiffs further contend that the court focused too heavily on broader public policy concerns rather than the scientific reliability of the experts’ analyses.

Following the dismissal of the federal MDL, Tylenol lawsuits continued progressing in several state courts, especially in California and Illinois. Defendants continued arguing that federal law preempts state law failure-to-warn claims because the FDA regulates acetaminophen labeling requirements.

However, California law sometimes allows broader liability theories than federal law alone, potentially allowing some state court cases to proceed.

As of August 20, 2024, Judge Denise Cote officially dismissed all federal cases pending in the Tylenol Autism Multidistrict Litigation after excluding plaintiffs’ expert testimony, and Judge Cote granted summary judgment in favor of the defendants.

Although plaintiffs filed an appeal, the dismissal significantly changed the direction of the litigation and shifted greater focus toward state court claims.

Judge Denise Cote issued several major rulings during the summer of 2024 that significantly impacted the future of the Tylenol autism MDL. Most notably, the court excluded expert testimony from Dr. Roberta Ness, one of the plaintiffs’ key causation experts.

At the time, more than 300 lawsuits remained pending, and plaintiffs alleged prenatal acetaminophen exposure caused autism and ADHD and depended on these experts to prove general causation.

The litigation’s future depended heavily on whether plaintiffs could successfully establish admissible expert causation testimony.

Judge Cote ruled that plaintiffs lacked sufficient scientific evidence linking prenatal Tylenol exposure to autism, leading to the exclusion of key expert testimony central to the litigation.

The ruling threatened the viability of hundreds of pending federal lawsuits, although many attorneys continued pursuing similar claims in state courts.

Plaintiffs introduced new testimony from Dr. Roberta Ness in an effort to revive portions of the Tylenol autism MDL after earlier expert testimony had been rejected.

Dr. Ness utilized Bradford Hill criteria and additional scientific analysis to support the plaintiffs’ claims that prenatal acetaminophen exposure may contribute to autism and ADHD diagnoses. Plaintiffs hoped the new testimony would survive future Daubert challenges and help reinstate portions of the litigation.

As of May 2024, plaintiffs were waiting to see whether the federal court would allow new expert testimony that could potentially revive portions of the Tylenol autism MDL. By the July deadline, defendants filed motions challenging the newly proposed expert opinions.

Until the court determined whether the new evidence was sufficient to support causation claims, some firms paused acceptance of new Tylenol autism cases.

The court overseeing the Tylenol autism MDL, with District Judge Denise Cote agreeing to hear evidence from a new expert regarding whether prenatal acetaminophen exposure may contribute to autism diagnoses later in life.

Defendants were given until July 2024 to file objections challenging the admissibility of the testimony. Plaintiffs hoped the new expert evidence could help revive portions of the litigation after the earlier dismissal of key expert opinions.

Judge Cote determined her earlier rulings had left only a narrow opportunity for the Mota plaintiffs to present new expert testimony, leading them to introduce Dr. Roberta Ness in an attempt to keep portions of the Tylenol autism litigation alive.

Defendants were given additional time to challenge whether Dr. Ness should be permitted to testify. Plaintiffs hoped her testimony could provide enough scientific support to allow certain claims to proceed despite earlier setbacks in the MDL.

Although Judge Denise Cote dismissed much of the federal Tylenol autism MDL in late 2023, she later allowed a separate group of plaintiffs known as the Mota plaintiffs to present new expert testimony because they were not part of the original MDL proceedings when the earlier decision was issued.

The Mota plaintiffs alleged prenatal acetaminophen exposure contributed to autism spectrum disorder and ADHD diagnoses in their children. Their expert witness, Dr. Roberta Ness, argued that multiple studies supported concerns regarding prenatal acetaminophen use and neurodevelopmental disorders.

The outcome of the separate Daubert proceedings involving Dr. Ness became one of the few remaining opportunities for portions of the Tylenol autism litigation to continue moving forward in federal court.

Following the dismissal of the federal MDL, many attorneys began preparing for increased Tylenol autism litigation in state courts across the country. Plaintiffs’ attorneys believed state court proceedings could provide another path for families pursuing compensation claims.

At the same time, related litigation involving alleged heavy metal contamination in baby food products continued gaining momentum nationwide.

Following Judge Denise Cote’s rulings excluding plaintiffs’ expert testimony, investors reacted positively to the dismissal of the federal Tylenol autism litigation. Kenvue, formerly associated with Johnson & Johnson, reportedly experienced a temporary stock increase after the court’s decision.

The ruling temporarily reduced concerns about large-scale federal liability tied to Tylenol autism lawsuits. However, company representatives also defended the safety profile of Tylenol, arguing the litigation risked creating confusion surrounding one of the most widely studied medications used during pregnancy.

A dedicated product liability attorney will gather as much medical evidence as possible to prove your child's ASD or ADHD diagnosis is connected to acetaminophen use during pregnancy. Usually, this will involve requesting copies of medical records from the time of the pregnancy. Additional information, such as receipts and purchase history, can also confirm prolonged exposure to Tylenol.

Your attorney will guide you through the process of proving Tylenol use during pregnancy and ensure that all relevant evidence is properly presented to support your claim. Keep in mind that numerous studies have demonstrated a correlation between the use of acetaminophen while pregnant with an increased risk of autism spectrum disorder diagnosis.

Throughout the studies, we note that higher levels of acetaminophen exposure equates to higher rates of autism. In fact, autism rates nearly mimic the levels of exposure, demonstrating a dose-dependent relationship in multiple published peer-reviewed studies. Further, numerous confounding factors were accounted for in demonstrating an elevated risk for autism.

Projected settlement values in Tylenol autism lawsuits are still being analyzed and reviewed according to the relevant data available and the outcomes of other prior mass tort cases. Individual values will likely depend heavily on the severity of the autism.

Autism Spectrum Disorder is classified into three main categories. ASD 1 is the least severe manifestation of the disorder, and ASD 3 is the most severe. Early settlement projections suggest the following potential values for ASD-level claims in acetaminophen autism lawsuits:

• ASD Level 1: $150,000 to $225,000
• ASD Level 2: $250,000 to $500,000
• ASD Level 3: Exceeding $500,000

Your potential settlement amount will vary depending on the amount of your economic and non-economic damages. Your unique financial losses may include pain and suffering, lost wages, and medical expenses, among others. When you partner with a skilled mass tort attorney at LLN, they can work with you to ensure that you receive the maximum compensation available and create a solid legal strategy that will strengthen your claim. 

Class action lawsuits involve multiple plaintiffs suffering the same injuries bringing suit against the same defendant or defendants. While some refer to the ongoing litigation as the 'Tylenol autism class action' or 'Tylenol class action lawsuit,' Tylenol autism lawsuits do not technically qualify as a class action because the plaintiffs are claiming a variety of injuries with varying degrees of severity, and the defendants are not necessarily the same. 

So because the defendant is the same but the injuries and damages are vastly different, these cases are being handled as federal Tylenol lawsuits, which are coordinated due to the large number of similar claims filed nationwide. However, since so many lawsuits have been filed by injured plaintiffs around the country, the federal court system adopted a different strategy.

Instead of forming a class action, a multi-district litigation (MDL) has been created to coordinate pre-trial discovery and motion hearings. This MDL consolidates acetaminophen lawsuits, including those alleging that prenatal exposure to Tylenol is linked to autism and ADHD. A Tylenol MDL ensures more efficient legal proceedings and consistent rulings across the nation. In general, the complaints claim that prenatal use of acetaminophen inhibits fetal brain development and increases the risk of autism spectrum diagnosis.

Tylenol Autism and ADHD Lawsuit MDL Update

Once the Judicial Panel on Multidistrict Litigation (JPML) consolidated the federal lawsuits, all Tylenol autism and ADHD claims filed in U.S. District Courts nationwide were transferred before Judge Denise Cote in the United States District Court for the Southern District of New York. The Tylenol autism MDL was centralized there to coordinate the federal proceedings.

This multidistrict litigation process allows the parties to streamline discovery, avoid duplicative litigation, and handle common legal and scientific issues more efficiently.

The defendants named in the Tylenol MDL include major retailers that sold Tylenol and generic acetaminophen products, including Walmart, CVS, Walgreens, Costco, and Rite Aid. In June 2023, Family Dollar, Dollar Tree, and 7-Eleven were also added as defendants.

The lawsuits additionally target drug manufacturers, including Johnson & Johnson, which distributes the medication under the Tylenol brand name.

The lawsuits allege that manufacturers and retailers ignored growing warnings from health professionals and failed to adequately warn consumers about the potential risks associated with prenatal acetaminophen exposure. Plaintiffs argue families were not properly informed about the alleged connection between Tylenol use during pregnancy and autism spectrum disorder (ASD) or ADHD diagnoses in children.

In many mass tort cases, drug manufacturers aggressively defend these lawsuits instead of quickly settling them. Retailers, however, may face additional public pressure because of concerns about consumer trust and brand reputation.

If you believe your child’s autism or ADHD diagnosis may be linked to prenatal Tylenol exposure, our law firm can review your case, evaluate potential compensable damages, and help determine whether you may qualify to file a Tylenol lawsuit.

Our experienced mass tort attorneys can assist at every stage of your Tylenol autism or ADHD lawsuit. Our legal team can gather evidence, build your case, and develop a strategy to support your claim to help you recover the maximum compensation possible.

With our skilled lawyers fighting for you, you may receive compensation for economic and non-economic damages due to Tylenol or generic acetaminophen exposure, including:

• Medical expenses and future treatment costs
• Pain and suffering
• Emotional distress
• Loss of quality of life
• Lost wages or income
• Permanent disability
• Lifelong personal care and shelter

We are committed to ensuring that our clients can pursue the best course of action to benefit them emotionally and financially. Throughout the lifecycle of your case, we will do our utmost to ensure that you understand your options, answer your questions, and prove you can depend on us to guide you through the legal process.